Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease
Dow Jones Newswires
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease
- Sources
- Dow Jones Newswires
- Markets
- Stocks
- Active symbols
- NASDAQ:GANX
- Language
- English